Noerr advised DiaSorin S.p.A. on the acquisition of a business portfolio from SIEMENS Healthineers

Noerr has accompanied Italian DiaSorin S.p.A. on the German-law aspects of the acquisition of the international micro-titre based ELISA immunodiagnostic business portfolio from Siemens Healthineers GmbH and affiliated companies (“SIEMENS Healthineers”). The publicly listed medical diagnostics specialist was advised by a team headed by Hamburg partners Björn Paulsen and Dr. Stephan Schulz.

Upon completion of the transaction, DiaSorin and certain of its affiliates will acquire the business portfolio and related tangible and intangible assets. The acquired assets include in particular the customers´ sales and distribution contracts, the installed base of instruments and the relevant intellectual property. In the context of the transaction, DiaSorin and SIEMENS Healthineers have entered into a manufacturing agreement with a term of three years regarding ELISA immunodiagnostic reagent kits which SIEMENS Healthineers will continue to manufacture, but will be distributed exclusively by DiaSorin. The total consideration to be paid is a medium double-digit million amount. Completion of the acquisition is subject to merger control approval and is expected to take place in the second half of the calendar year 2017.

For the transaction Noerr worked together with the Italian law firm Gatti Pavesi Bianchi, Milan, who was acting as international lead counsel.

Advisor of DiaSorin S.p.A.: Noerr LLP

Björn Paulsen, Dr. Stephan Schulz (joint project lead, Corporate M&A, both Hamburg); Ariane Neubauer (Corporate M&A, Berlin); Dr. Alexander Birnstiel (Antitrust, Munich); Dr. Tobias Bosch, Jessica Loew (IP, Berlin); Dr. Arun Kapoor (Commercial, Munich).

Associates: Dr. Sarah Götze (Corporate M&A, Hamburg); Stefan Bauer (Antitrust, Munich).

Gatti Pavesi Bianchi: Stefano Valerio, Giorgio Groppi, Milan.